- Home
- SRE vs ZTS Comparison
SRE vs ZTS Comparison
Compare SRE & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRE | ZTS |
|---|---|---|
| Founded | 1998 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4B | 54.8B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | SRE | ZTS |
|---|---|---|
| Price | $87.17 | $124.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | $97.00 | ★ $166.60 |
| AVG Volume (30 Days) | 3.6M | ★ 4.4M |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.96% | 1.70% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | 3.25 | ★ 5.94 |
| Revenue | ★ $13,711,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | $6.94 | $3.04 |
| Revenue Next Year | $5.39 | $4.96 |
| P/E Ratio | $26.83 | ★ $21.05 |
| Revenue Growth | ★ 6.14 | 2.68 |
| 52 Week Low | $61.90 | $115.25 |
| 52 Week High | $95.72 | $177.40 |
Technical Indicators
Market Signals| Indicator | SRE | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 49.45 |
| Support Level | $83.91 | $122.97 |
| Resistance Level | $92.53 | $127.12 |
| Average True Range (ATR) | 2.08 | 2.87 |
| MACD | -0.26 | -0.21 |
| Stochastic Oscillator | 37.82 | 36.48 |
Price Performance
Historical ComparisonAbout SRE DBA Sempra
Sempra Energy serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. Sempra Infrastructure partners, of which Sempra will hold a 25% ownership, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.